United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 851,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "5a02bc3f-f0bd-43cc-916c-8d6f5c09d738",
"title": "Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug",
"description": "Key Highlights:\n Pfizer and Arvinas plan to submit a new drug application for vepdegestrant in late 2025. Analysts forecast an average price target of $28",
"keywords": "GuruFocus, Article, News, GuruFocus News, PFE",
"snippet": "Key Highlights:\n\nPfizer and Arvinas plan to submit a new drug application for vepdegestrant in late 2025.\n\nAnalysts forecast an average price target of $28.57 f...",
"url": "https://www.gurufocus.com/news/2899952/pfizer-and-arvinas-plan-fda-submission-for-breast-cancer-drug",
"image_url": "https://static.gurufocus.com/logos/0C00000C7U.png?20",
"language": "en",
"published_at": "2025-05-31T15:55:39.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.382652,
"sentiment_score": -0.063329,
"highlights": [
{
"highlight": "Key Highlights:\n\n<em>Pfizer</em> and Arv[+258 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> (PFE, Financial) and Arv[+259 characters]",
"sentiment": -0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nAccording[+317 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Investors seeking comprehensive estimate[+280 characters]",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "According to GuruFocus estimates, the GF[+182 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For a deeper dive into the data, explore[+53 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> and Arvinas Plan FDA Submission for Breast Cancer Drug",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 45.382652,
"sentiment_score": -0.063329,
"highlights": [
{
"highlight": "Key Highlights:\n\n<em>Pfizer</em> and Arv[+258 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> (PFE, Financial) and Arv[+259 characters]",
"sentiment": -0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nAccording[+317 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Investors seeking comprehensive estimate[+280 characters]",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "According to GuruFocus estimates, the GF[+182 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For a deeper dive into the data, explore[+53 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> and Arvinas Plan FDA Submission for Breast Cancer Drug",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "bcc6b3d4-e01a-425a-8127-d386061e2fbb",
"title": "Gilead Sciences (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"description": "Gilead Sciences' Trodelvy shows promising results in a Phase 3 trial when paired with Merck's Keytruda. Average analyst price target for GILD suggests a",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences' Trodelvy shows promising results in a Phase 3 trial when paired with Merck’s Keytruda.\n\nAverage analyst price target for GILD suggests a pote...",
"url": "https://www.gurufocus.com/news/2899947/gilead-sciences-gild-reports-positive-results-for-trodelvy-combo-in-breast-cancer-study",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-05-31T14:55:41.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.14494,
"sentiment_score": 0.078686,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>' Trode[+314 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD)[+283 characters]",
"sentiment": -0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts' Price Projections\n[+269 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+293 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The estimated GF Value for <em>Gilead</e[+321 characters]",
"sentiment": 0.8144,
"highlighted_in": "main_text"
},
{
"highlight": "For further insights, visit the <em>Gile[+59 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"sentiment": -0.2023,
"highlighted_in": "title"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 112.47293,
"sentiment_score": 0.078686,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>' Trode[+314 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD)[+283 characters]",
"sentiment": -0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts' Price Projections\n[+260 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+275 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The estimated GF Value for <em>Gilead</e[+312 characters]",
"sentiment": 0.8144,
"highlighted_in": "main_text"
},
{
"highlight": "For further insights, visit the <em>Gile[+50 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"sentiment": -0.2023,
"highlighted_in": "title"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.13794,
"sentiment_score": 0.078686,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>' Trode[+314 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD)[+283 characters]",
"sentiment": -0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts' Price Projections\n[+269 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+293 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The estimated GF Value for <em>Gilead</e[+321 characters]",
"sentiment": 0.8144,
"highlighted_in": "main_text"
},
{
"highlight": "For further insights, visit the <em>Gile[+59 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"sentiment": -0.2023,
"highlighted_in": "title"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.12971,
"sentiment_score": 0.078686,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em>' Trode[+314 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD)[+283 characters]",
"sentiment": -0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts' Price Projections\n[+269 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+293 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The estimated GF Value for <em>Gilead</e[+321 characters]",
"sentiment": 0.8144,
"highlighted_in": "main_text"
},
{
"highlight": "For further insights, visit the <em>Gile[+59 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD) Reports Positive Results for Trodelvy Combo in Breast Cancer Study",
"sentiment": -0.2023,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "06079ab3-efc3-4d77-addb-42429a44dbe6",
"title": "Pfizer, Arvinas to seek FDA nod for cancer therapy in H2 (PFE)",
"description": "Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more here.",
"keywords": "",
"snippet": "Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and Drug Administration (FDA) in H2 20...",
"url": "https://seekingalpha.com/news/4454039-pfizer-arvinas-seek-fda-nod-cancer-therapy-h2",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178648915/image_2178648915.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2025-05-31T14:02:41.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARVN",
"name": "Arvinas, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 57.62878,
"sentiment_score": -0.48895,
"highlights": [
{
"highlight": "Pfizer (NYSE:PFE) and <em>Arvinas</em> ([+253 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Pfizer, <em>Arvinas</em> to seek FDA nod for cancer therapy in H2 (PFE)",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 42.121418,
"sentiment_score": -0.48895,
"highlights": [
{
"highlight": "<em>Pfizer</em> (<em>NYSE:PFE</em>) and [+253 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em>, Arvinas to seek FDA nod for cancer therapy in H2 (PFE)",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "397c2098-b811-44a8-9ba7-2a6966e5b96e",
"title": "Gilead Sciences Inc (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"description": "Summary Gilead Sciences Inc (GILD) has announced that its drug Trodelvy® (sacituzumab govitecan-hziy), when combined with Keytruda® (pembrolizumab), significa",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Summary\n\nGilead Sciences Inc (GILD, Financial) has announced that its drug Trodelvy® (sacituzumab govitecan-hziy), when combined with Keytruda® (pembrolizumab...",
"url": "https://www.gurufocus.com/news/2899943/gilead-sciences-inc-gild-announces-promising-results-for-trodelvy-and-keytruda-combination-in-breast-cancer-treatment-gild-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:01:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.39114,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+342 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> <em>Inc</em> (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 94.42236,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+333 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> Inc (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.37713,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+342 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> <em>Inc</em> (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.36574,
"sentiment_score": -0.56015,
"highlights": [
{
"highlight": "Summary\n\n<em>Gilead</em> <em>Sciences</e[+342 characters]",
"sentiment": -0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em> <em>Inc</em> (GILD) Announces Promising Results for Trodelvy and Keytruda Combination in Breast Cancer Treatment | GILD stock news",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "4e9d4344-330d-4bdd-a1ff-74bda65beea6",
"title": "Lemonade (LMND) Leads Financial Stocks with 8.5% Weekly Gain",
"description": "Summary:\n Lemonade Inc. (LMND) led financial stocks with an 8.5% rise for the week ending May 30, 2025. Average analyst price target for LMND suggests a p",
"keywords": "GuruFocus, Article, News, GuruFocus News, LMND",
"snippet": "Summary:\n\nLemonade Inc. (LMND, Financial) led financial stocks with an 8.5% rise for the week ending May 30, 2025.\n\nAverage analyst price target for LMND sugges...",
"url": "https://www.gurufocus.com/news/2899951/lemonade-lmnd-leads-financial-stocks-with-85-weekly-gain",
"image_url": "https://static.gurufocus.com/logos/0C0000BUVD.png?20",
"language": "en",
"published_at": "2025-05-31T15:55:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LMND",
"name": "Lemonade, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 60.711227,
"sentiment_score": 0.439617,
"highlights": [
{
"highlight": "Summary:\n\n<em>Lemonade</em> <em>Inc</em>[+290 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Notably, this upward momentum in <em>Lem[+327 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "For a more comprehensive breakdown of th[+261 characters]",
"sentiment": 0.3102,
"highlighted_in": "main_text"
},
{
"highlight": "Evaluating Future Value: The GF Value Pe[+254 characters]",
"sentiment": 0.8225,
"highlighted_in": "main_text"
},
{
"highlight": "For further details on this valuation me[+104 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Lemonade</em> (LMND) Leads Financial Stocks with 8.5% Weekly Gain",
"sentiment": 0.5267,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b010b2ba-0d96-4bf3-b981-991e69908e28",
"title": "SDS: A Good Hedging Tool With A Caveat",
"description": "SDS offers -2x S&P 500 exposure with lower decay than peers, useful for tactical hedging if actively monitored. Learn why SDS ETF is a hold.",
"keywords": "",
"snippet": "The ProShares UltraShort S&P500 ETF (NYSEARCA: SDS ) aims to provide the daily return that corresponds to twice the inverse (-2X) of the daily return of the S&P...",
"url": "https://seekingalpha.com/article/4791444-sds-good-hedging-tool-with-caveat",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456117283/image_1456117283.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-31T15:34:29.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "SDS",
"name": "ProShares UltraShort S&P500",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "etf",
"industry": "N/A",
"match_score": 105.45729,
"sentiment_score": 0,
"highlights": [
{
"highlight": "The <em>ProShares</em> <em>UltraShort</e[+185 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9a85b351-7ba3-4a7b-ada1-9e4d5ca5fb17",
"title": "ECAT: Saba's Activism Drives Double-Digit Yield, Upcoming Vote Is Key (NYSE:ECAT)",
"description": "ECAT offers a compelling 22.84% yield and trades at a 4.37% discount to NAV. Click to learn about the proxy vote, Saba's impact, and why ECAT is a hold.",
"keywords": "",
"snippet": "BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT ) is a closed-end fund with roughly $1.6 billion in assets under management and trading at a 4.37% disco...",
"url": "https://seekingalpha.com/article/4791443-blackrock-ecat-saba-capital-activism-drives-double-digit-yield-upcoming-vote-is-key",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689041338/image_1689041338.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-31T15:06:18.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 14.578384,
"sentiment_score": 0.836,
"highlights": [
{
"highlight": "<em>BlackRock</em> ESG Capital Allocatio[+162 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "f5a0ebdb-1877-4a86-b38d-97fb17f9e92c",
"title": "Deutsche Bank Upgrades Southwest Airlines (LUV) to Buy",
"description": "Summary:\n Deutsche Bank upgrades Southwest Airlines to a Buy due to strategic changes and potential growth. Average price target suggests potential downsi",
"keywords": "GuruFocus, Article, News, GuruFocus News, LUV",
"snippet": "Summary:\n\nDeutsche Bank upgrades Southwest Airlines to a Buy due to strategic changes and potential growth.\n\nAverage price target suggests potential downside, t...",
"url": "https://www.gurufocus.com/news/2899946/deutsche-bank-upgrades-southwest-airlines-luv-to-buy",
"image_url": "https://static.gurufocus.com/logos/0C00000955.png?20",
"language": "en",
"published_at": "2025-05-31T14:55:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LUV",
"name": "Southwest Airlines Co.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 87.23694,
"sentiment_score": 0.133333,
"highlights": [
{
"highlight": "Summary:\n\nDeutsche Bank upgrades <em>Sou[+371 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "Analyst Price Targets and Implications\n\n[+296 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details, investors can visit[+298 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Exploring the GF Value Estimate\n\nDelving[+242 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "For in-depth data, investors should chec[+89 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Deutsche Bank Upgrades <em>Southwest</em> <em>Airlines</em> (LUV) to Buy",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "284bb867-0ecb-42b3-af43-edb74f797857",
"title": "CVR Energy Stock: Recovery Can Continue (NYSE:CVI)",
"description": "CVR Energy’s margins and cash flow improve with crack spreads and refinery turnaround; debt cuts and dividends likely in 2026. Find out why CVI stock is a buy.",
"keywords": "",
"snippet": "Shares of CVR Energy (NYSE: CVI ) have been a poor performer over the past year, as a weaker refining environment and high turnaround costs forced it to suspend...",
"url": "https://seekingalpha.com/article/4791438-cvr-energys-recovery-can-continue",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1080486186/image_1080486186.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-31T14:45:00.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CVI",
"name": "CVR Energy, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 137.90463,
"sentiment_score": -0.4221,
"highlights": [
{
"highlight": "Shares of <em>CVR</em> <em>Energy</em> ([+170 characters]",
"sentiment": -0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVR</em> <em>Energy</em> Stock: Recovery Can Continue (<em>NYSE:CVI</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b17ee25b-3de1-4277-8ccc-5075afaec631",
"title": "Better AI Stock: Palantir vs. BigBear.ai",
"description": "Palantir and BigBear.ai are artificial intelligence (AI) stocks involved in the defense industry. Both companies are also working to move beyond the U.S. government. Two of the leading artificial intelligence (AI) stocks over the past year are Palantir Technologies (NASDAQ: PLTR) and BigBear.ai (NYSE: BBAI).",
"keywords": "Palantir, revenue growth, AI company, AI stock, artificial intelligence, systems integrator",
"snippet": "Key Points\n\nPalantir and BigBear.ai are artificial intelligence (AI) stocks involved in the defense industry.\n\nBoth companies are also working to move beyond th...",
"url": "https://finance.yahoo.com/news/better-ai-stock-palantir-vs-143000857.html",
"image_url": "https://s.yimg.com/ny/api/res/1.2/TZGLKUaKqdWyoPJVOJwmuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/b94e9f3d61f07bec981b16318f16ee34",
"language": "en",
"published_at": "2025-05-31T14:30:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "PLTR",
"name": "Palantir Technologies Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 23.199604,
"sentiment_score": 0.8779,
"highlights": [
{
"highlight": "However, their revenue growth and margin[+268 characters]",
"sentiment": 0.8779,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "611a224c-4099-4900-baa5-b0c907a34d74",
"title": "Tempus AI Inc (TEM) Launches Fuses Program to Revolutionize Precision Medicine | TEM stock news",
"description": "Summary Tempus AI Inc (TEM), a leader in AI-driven precision medicine, announced the launch of its Fuses program, designed to leverage its extensive proprietary",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "Summary\n\nTempus AI Inc (TEM, Financial), a leader in AI-driven precision medicine, announced the launch of its Fuses program, designed to leverage its extensive...",
"url": "https://www.gurufocus.com/news/2899941/tempus-ai-inc-tem-launches-fuses-program-to-revolutionize-precision-medicine-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:47.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 108.49646,
"sentiment_score": 0.39598,
"highlights": [
{
"highlight": "Summary\n\n<em>Tempus</em> <em>AI</em> <em[+205 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+176 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nAs [+308 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "The Fuses program is an initiative by <e[+322 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Tempus</em> <em>AI</em> <em>Inc</em> (TEM) Launches Fuses Program to Revolutionize Precision Medicine | TEM stock news",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "ef43e868-cebc-43a5-83ce-e76ecc4918db",
"title": "Prediction: Caterpillar's Stock Becomes a Buy When This Key Number Turns Around",
"description": "The heavy machinery maker's retail sales to its end users appear to be in an uptrend. Dealer inventory is lower than expected, indicating that sales growth is likely to follow. This key metric below will guide the way to increased profitability for Caterpillar.",
"keywords": "Caterpillar, Caterpillar stock, retail sales, operating profit, Dealer inventory, Machine sales",
"snippet": "Key Points\n\nThe heavy machinery maker's retail sales to its end users appear to be in an uptrend.\n\nDealer inventory is lower than expected, indicating that sale...",
"url": "https://finance.yahoo.com/news/prediction-caterpillars-stock-becomes-buy-141500349.html",
"image_url": "https://media.zenfs.com/en/motleyfool.com/9d7d5de6074b80c6ed22a9b1d8ed0cc6",
"language": "en",
"published_at": "2025-05-31T14:15:00.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "CAT",
"name": "Caterpillar Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 32.510963,
"sentiment_score": 0.64744,
"highlights": [
{
"highlight": "This key metric below will guide the way[+298 characters]",
"sentiment": 0.9169,
"highlighted_in": "main_text"
},
{
"highlight": "The case for buying <em>Caterpillar</em>[+228 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Its dealers' inventory position in the f[+229 characters]",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Before supporting these points in detail[+258 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Data source: <em>Caterpillar</em> presen[+283 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "727adca4-03df-461f-b2b6-d794c21bc248",
"title": "Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Libtayo in High-Risk CSCC | REGN stock news",
"description": "Summary Regeneron Pharmaceuticals Inc (REGN) has announced promising results from its Phase 3 C-POST trial, evaluating the PD-1 inhibitor Libtayo® (cemiplimab)",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Summary\n\nRegeneron Pharmaceuticals Inc (REGN, Financial) has announced promising results from its Phase 3 C-POST trial, evaluating the PD-1 inhibitor Libtayo® ...",
"url": "https://www.gurufocus.com/news/2899945/regeneron-pharmaceuticals-inc-regn-announces-promising-phase-3-trial-results-for-libtayo-in-highrisk-cscc-regn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:01:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 103.061874,
"sentiment_score": 0.37095,
"highlights": [
{
"highlight": "Summary\n\n<em>Regeneron</em> <em>Pharmace[+241 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em> (REGN) Announces Promising Phase 3 Trial Results for Libtayo in High-Risk CSCC | REGN stock news",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "823164da-ec1c-48cf-be21-2962d5bdd948",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing",
"description": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and",
"keywords": "GuruFocus, Article, News, Marketwired, REGN",
"snippet": "Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)\n\nLibtayo also demonstrated 80% and...",
"url": "https://www.gurufocus.com/news/2899929/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 19.57739,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.576618,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.575602,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.573944,
"sentiment_score": -0.075325,
"highlights": [
{
"highlight": "., May 31, 2025 (GLOBE NEWSWIRE) -- <em>[+264 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "You may also report side effects to <em>[+128 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Forward-Looking Statements and Use of Di[+219 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Financial and other information about Re[+232 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "7a204204-ec07-467a-84b4-9dde533d59d9",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing | REGN Stock News",
"description": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery. Trial reveals 87% disease",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery.\n\nTrial reveals 87% disease-free s...",
"url": "https://www.gurufocus.com/news/2899915/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging-regn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008R4.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:27.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.920944,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.919144,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 40.91459,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.910954,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "dc588c3d-74f2-4636-a1e8-86fbff5774b6",
"title": "June 2025 Watchlist: Best Canadian Cannabis Stocks for Growth",
"description": "Are Canadian Pot Stocks a Buy in June?",
"keywords": "",
"snippet": "Canadian Cannabis Powerhouses: Stocks to Watch This Month\n\nAs of June 2025, the U.S. cannabis industry continues its rapid expansion. Projections estimate the m...",
"url": "https://marijuanastocks.com/june-2025-watchlist-best-canadian-cannabis-stocks-for-growth/",
"image_url": "https://marijuanastocks.com/wp-content/uploads/2023/07/Top-Marijuana-Stocks-July-2023.png",
"language": "en",
"published_at": "2025-05-31T14:00:52.000000Z",
"source": "marijuanastocks.com",
"relevance_score": null,
"entities": [
{
"symbol": "APHA",
"name": "Tilray, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.018757,
"sentiment_score": 0.369471,
"highlights": [
{
"highlight": "These companies are <em>Tilray</em> Bran[+224 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "[Read More] 3 Marijuana Stocks To Watch [+307 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "While U.S. federal restrictions limit ca[+289 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Currently, <em>Tilray</em> does not oper[+243 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "As regulations evolve, <em>Tilray</em> i[+315 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Despite the loss, <em>Tilray</em> remain[+229 characters]",
"sentiment": 0.9132,
"highlighted_in": "main_text"
},
{
"highlight": "With a mix of international presence, U.[+245 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TLRY",
"name": "Tilray, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 42.173557,
"sentiment_score": 0.369471,
"highlights": [
{
"highlight": "These companies are <em>Tilray</em> Bran[+224 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "[Read More] 3 Marijuana Stocks To Watch [+334 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "While U.S. federal restrictions limit ca[+289 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Currently, <em>Tilray</em> does not oper[+243 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "As regulations evolve, <em>Tilray</em> i[+315 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Despite the loss, <em>Tilray</em> remain[+229 characters]",
"sentiment": 0.9132,
"highlighted_in": "main_text"
},
{
"highlight": "With a mix of international presence, U.[+245 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "OGI",
"name": "OrganiGram Holdings Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.191177,
"sentiment_score": 0.251,
"highlights": [
{
"highlight": "These companies are Tilray Brands, <em>O[+233 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "(NASDAQ: TLRY) <em>Organigram</em> <em>H[+280 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "[Read More] These Top Marijuana Stocks C[+288 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ACB",
"name": "Aurora Cannabis Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.527245,
"sentiment_score": 0.245633,
"highlights": [
{
"highlight": "These companies are Tilray Brands, Organ[+233 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "(NASDAQ: OGI) <em>Aurora</em> <em>Cannab[+222 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Marijuana Stocks to Add to Your Watchlis[+293 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "20363e01-6f87-4365-86a7-fbc211cc40c0",
"title": "These Are Stocks You Should Watch in June",
"description": "Stocks soared in May, boosted by easing trade tensions, solid corporate earnings and signs of economic resilience. Trade and tax policy are likely to remain Wall Street's focus in June.",
"keywords": "",
"snippet": "Stocks soared in May, lifted by easing trade tensions between the U.S. and China, a strong end to first-quarter earnings season, and evidence the economy remain...",
"url": "https://www.investopedia.com/stocks-to-watch-in-june-2025-aapl-tsla-nke-unh-11745715",
"image_url": "https://www.investopedia.com/thmb/hkAbBOfNctGtY31ZQG5n-Aa3ss4=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-22153794291-ec86f34cb131450d813c61491fad6d93.jpg",
"language": "en",
"published_at": "2025-05-31T11:00:00.000000Z",
"source": "investopedia.com",
"relevance_score": null,
"entities": [
{
"symbol": "FSLR",
"name": "First Solar, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 11.23683,
"sentiment_score": 0.69555,
"highlights": [
{
"highlight": "Shares of Enphase Energy (ENPH) and SunR[+302 characters]",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Shares of Enphase Energy are down about [+116 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 11.252194,
"sentiment_score": 0.37,
"highlights": [
{
"highlight": "<em>Tesla</em>\n\nNow that CEO Elon Musk h[+199 characters]",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Tesla</em> is reportedly aiming to l[+286 characters]",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "The public and Wall Street’s perceptio[+322 characters]",
"sentiment": 0.7003,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RUN",
"name": "Sunrun Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 13.893623,
"sentiment_score": 0.69555,
"highlights": [
{
"highlight": "Shares of Enphase Energy (ENPH) and <em>[+293 characters]",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Shares of Enphase Energy are down about [+107 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ENPH",
"name": "Enphase Energy, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 16.901293,
"sentiment_score": 0.56465,
"highlights": [
{
"highlight": "Shares of <em>Enphase</em> <em>Energy</e[+302 characters]",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Shares of <em>Enphase</em> <em>Energy</e[+116 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 10.770767,
"sentiment_score": 0.71585,
"highlights": [
{
"highlight": "<em>Apple</em>\n\nTariffs have been the pr[+338 characters]",
"sentiment": 0.9253,
"highlighted_in": "main_text"
},
{
"highlight": "Executives touted <em>Apple</em> Intelli[+336 characters]",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Apple</em> has disappointed Wall Str[+217 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Apple</em> shares, weighed down by P[+310 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UNHD.BA",
"name": "UNITEDHEALTH GROUP",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 24.04918,
"sentiment_score": 0.384033,
"highlights": [
{
"highlight": "<em>UnitedHealth</em> <em>Group</em>\n\n<e[+297 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "The stock slumped by double-digits again[+286 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Of the 16 <em>UnitedHealth</em> analysts[+263 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "09ff62bd-6006-4e28-ae83-5427d57ca9c0",
"title": "Delaware Court Further Extends Topping Period for Citgo Sale Process to June 18, 2025; Confirms Other Deadlines | GDRZF Stock News",
"description": "Delaware court extends Citgo sale Topping Period deadline to June 18, 2025. Several key deadlines confirmed for the ongoing Citgo sale process. Gold Reserv",
"keywords": "GuruFocus, Article, News, GuruFocus News, GDRZF",
"snippet": "Delaware court extends Citgo sale Topping Period deadline to June 18, 2025.\n\nSeveral key deadlines confirmed for the ongoing Citgo sale process.\n\nGold Reserve L...",
"url": "https://www.gurufocus.com/news/2899873/delaware-court-further-extends-topping-period-for-citgo-sale-process-to-june-18-2025-confirms-other-deadlines-gdrzf-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T07:00:13.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GDRZF",
"name": "Gold Reserve Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 54.654892,
"sentiment_score": 0.549525,
"highlights": [
{
"highlight": "<em>Gold</em> <em>Reserve</em> Ltd. supp[+274 characters]",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "This move was in response to a motion by[+319 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "Stakeholders like Vitol, Inc., Rusoro Mi[+290 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "Delaware Court Further Extends Topping Period for Citgo Sale Process to June 18, 2025; Confirms Other Deadlines | <em>GDRZF</em> Stock News",
"sentiment": 0.128,
"highlighted_in": "title"
}
]
},
{
"symbol": "RMLFF",
"name": "Rusoro Mining Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 60.56163,
"sentiment_score": 0.7003,
"highlights": [
{
"highlight": "., <em>Rusoro</em> <em>Mining</em> <em>L[+253 characters]",
"sentiment": 0.7003,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RML.V",
"name": "Rusoro Mining Ltd.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Basic Materials",
"match_score": 60.542572,
"sentiment_score": 0.7003,
"highlights": [
{
"highlight": "., <em>Rusoro</em> <em>Mining</em> <em>L[+253 characters]",
"sentiment": 0.7003,
"highlighted_in": "main_text"
}
]
}
]
}
]
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 1233,
"sentiment_avg": 0.2857954119427152
}
]
}
Other details
Entity count
- 32,649